Tin tức & Cập nhật

Sustained benefits with ocrelizumab in relapsing-remitting MS
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022 bởiRoshini Claire Anthony

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
How does IV edaravone fare for ALS in the real world?
How does IV edaravone fare for ALS in the real world?
10 May 2022